CR20170104A - Uso de paneles de genes mutantes de fgfr en la identificación de pacientes con cáncer que responderán al tratamiento con un inhibidor de fgfr - Google Patents
Uso de paneles de genes mutantes de fgfr en la identificación de pacientes con cáncer que responderán al tratamiento con un inhibidor de fgfrInfo
- Publication number
- CR20170104A CR20170104A CR20170104A CR20170104A CR20170104A CR 20170104 A CR20170104 A CR 20170104A CR 20170104 A CR20170104 A CR 20170104A CR 20170104 A CR20170104 A CR 20170104A CR 20170104 A CR20170104 A CR 20170104A
- Authority
- CR
- Costa Rica
- Prior art keywords
- fgfr
- treatment
- cancer patients
- responsive
- mutant gene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2531/00—Reactions of nucleic acids characterised by
- C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
- C12Q2531/113—PCR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
En la presente descripción, se describen métodos para identificar un paciente con cáncer que responderá al tratamiento con un inhibidor del receptor del factor de crecimiento de fibroblastos (FGFR) y métodos para tratar pacientes con cáncer. Los métodos implican evaluar una muestra biológica del paciente para detectar la presencia de uno o más mutantes de FGFR a partir de un panel de genes mutantes de FGFR. En la presente descripción se describen, además, estuches e iniciadores para identificar la presencia de uno o más genes mutantes de FGFR en una muestra biológica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462056159P | 2014-09-26 | 2014-09-26 | |
| PCT/US2015/050996 WO2016048833A2 (en) | 2014-09-26 | 2015-09-18 | Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20170104A true CR20170104A (es) | 2017-05-31 |
Family
ID=54337343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20170104A CR20170104A (es) | 2014-09-26 | 2015-09-18 | Uso de paneles de genes mutantes de fgfr en la identificación de pacientes con cáncer que responderán al tratamiento con un inhibidor de fgfr |
Country Status (38)
| Country | Link |
|---|---|
| US (3) | US20160090633A1 (es) |
| EP (2) | EP3198033B1 (es) |
| JP (4) | JP6766037B2 (es) |
| KR (3) | KR102470456B1 (es) |
| CN (2) | CN107002141B (es) |
| AR (1) | AR102345A1 (es) |
| AU (3) | AU2015321626B2 (es) |
| CA (2) | CA2962075C (es) |
| CO (1) | CO2017003528A2 (es) |
| CR (1) | CR20170104A (es) |
| CY (1) | CY1125190T1 (es) |
| DK (1) | DK3198033T3 (es) |
| EA (1) | EA037920B1 (es) |
| EC (1) | ECSP17025787A (es) |
| ES (1) | ES2912567T3 (es) |
| GT (1) | GT201700059A (es) |
| HR (1) | HRP20220496T1 (es) |
| HU (1) | HUE058219T2 (es) |
| IL (3) | IL291633B2 (es) |
| JO (1) | JO3681B1 (es) |
| LT (1) | LT3198033T (es) |
| MA (1) | MA40761B1 (es) |
| MX (2) | MX392774B (es) |
| MY (1) | MY194567A (es) |
| NI (1) | NI201700035A (es) |
| PH (1) | PH12017500556A1 (es) |
| PL (1) | PL3198033T3 (es) |
| PT (1) | PT3198033T (es) |
| RS (1) | RS63178B1 (es) |
| SG (1) | SG11201702381QA (es) |
| SI (1) | SI3198033T1 (es) |
| SM (1) | SMT202200177T1 (es) |
| SV (1) | SV2017005415A (es) |
| TW (1) | TWI706136B (es) |
| UA (1) | UA122564C2 (es) |
| UY (1) | UY36325A (es) |
| WO (1) | WO2016048833A2 (es) |
| ZA (1) | ZA201702899B (es) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2886002C (en) | 2012-09-27 | 2020-06-09 | Chugai Seiyaku Kabushiki Kaisha | Fgfr3 fusion gene and pharmaceutical drug targeting same |
| EP3098312B1 (en) * | 2014-01-24 | 2023-07-19 | Japanese Foundation For Cancer Research | Novel fusant and method for detecting same |
| MA39784B1 (fr) | 2014-03-26 | 2021-03-31 | Astex Therapeutics Ltd | Combinaisons des inhibiteurs du fgfr et du cmet destinées au traitement du cancer |
| CR20170104A (es) | 2014-09-26 | 2017-05-31 | Janssen Pharmaceutica Nv | Uso de paneles de genes mutantes de fgfr en la identificación de pacientes con cáncer que responderán al tratamiento con un inhibidor de fgfr |
| JO3695B1 (ar) | 2015-02-10 | 2020-08-27 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n- (3.5- ثنائي ميثوكسي فينيل)-n-(1-ميثيل إيثيل)-n- 3-( ميثيل-h1-بيرازول-4-يل) كينوكسالين-6-يل) إيثان- 1.2-ثنائي الأمين) |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| EP3424505A4 (en) * | 2016-03-04 | 2019-10-16 | Taiho Pharmaceutical Co., Ltd. | PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| JOP20190280A1 (ar) | 2017-06-02 | 2019-12-02 | Janssen Pharmaceutica Nv | مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية |
| EP3639039A4 (en) | 2018-07-27 | 2021-05-19 | Zepto Life Technology, LLC | SYSTEM AND PROCEDURE FOR GMR-BASED DETECTION OF BIOMARKERS |
| EA202190826A1 (ru) * | 2018-09-21 | 2021-06-16 | Янссен Фармацевтика Нв | Лечение холангиокарциномы |
| CN113423402A (zh) * | 2019-02-12 | 2021-09-21 | 詹森药业有限公司 | 癌症治疗 |
| EP3946340A1 (en) | 2019-03-29 | 2022-02-09 | Janssen Pharmaceutica NV | Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma |
| CN113645974A (zh) * | 2019-03-29 | 2021-11-12 | 詹森药业有限公司 | 用于治疗尿路上皮癌的fgfr酪氨酸激酶抑制剂 |
| US20220233537A1 (en) * | 2019-05-31 | 2022-07-28 | Qed Therapeutics, Inc. | Methods of treating urinary system cancers |
| CN110241183B (zh) * | 2019-06-13 | 2022-10-28 | 南京世和基因生物技术股份有限公司 | 一种fgfr融合基因的检测方法、试剂盒以及探针库 |
| US20220267452A1 (en) * | 2019-07-12 | 2022-08-25 | Chugai Seiyaku Kabushiki Kaisha | Anti-mutation type fgfr3 antibody and use therefor |
| CN115335701A (zh) * | 2019-09-09 | 2022-11-11 | 泽普托生命技术有限责任公司 | 用于检测核酸中基因变异的系统和方法 |
| US20220348662A1 (en) | 2019-09-26 | 2022-11-03 | Janssen Pharmaceutica Nv | Use of fgfr inhibitors in fgfr-genetically altered cancers to enhance patient response to immune checkpoint inhibitors in sequential treatment settings |
| US12600825B2 (en) | 2020-01-08 | 2026-04-14 | Zepto Life Technology, Inc. | Polymer compositions and biosurfaces comprising them on sensors |
| TWI900527B (zh) | 2020-02-12 | 2025-10-11 | 比利時商健生藥品公司 | 用於治療尿路上皮癌的ｆｇｆｒ酪胺酸激酶抑制劑和抗ｐｄ１藥劑 |
| PH12022552093A1 (en) * | 2020-02-12 | 2023-11-29 | Janssen Pharmaceutica Nv | Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer |
| AU2021254793A1 (en) * | 2020-04-15 | 2022-11-17 | Clovis Oncology, Inc. | Immunostimulatory agents in combination with angiogenesis inhibitors |
| CN111440790A (zh) * | 2020-05-08 | 2020-07-24 | 公安部物证鉴定中心 | 唾液斑迹dna和rna同时提取的方法 |
| US20230321087A1 (en) | 2020-09-14 | 2023-10-12 | Janssen Pharmaceutica Nv | Fgfr inhibitor combination therapies |
| CN112143815B (zh) * | 2020-11-25 | 2021-02-26 | 江苏申基生物科技有限公司 | 一种用于检测人fgfr2基因融合突变的核酸组合物、试剂盒及检测方法 |
| US20250000858A1 (en) | 2021-05-19 | 2025-01-02 | Janssen Pharmaceutica Nv | Fgfr tyrosine kinase inhibitors for the treatment of advanced solid tumors |
| EP4415692A1 (en) | 2021-10-12 | 2024-08-21 | TARIS Biomedical LLC | Erdafitinib formulations and systems for intravesical administration |
| KR20240145513A (ko) | 2022-02-18 | 2024-10-07 | 타리스 바이오메디컬 엘엘씨 | 에르다피티닙 제형 및 방광내 투여를 위한 삼투성 시스템 |
| EP4665342A1 (en) | 2023-02-13 | 2025-12-24 | TARIS Biomedical LLC | Erdafitinib for intravesical administration for use in the treatment of bladder cancer |
| CN120813357A (zh) | 2023-02-13 | 2025-10-17 | 詹森药业有限公司 | 用于治疗高风险非肌层浸润性膀胱癌的fgfr酪氨酸激酶抑制剂 |
| JP2026506041A (ja) | 2023-02-17 | 2026-02-20 | タリス バイオメディカル エルエルシー | 膀胱がんの治療における使用のための膀胱内投与のためのエルダフィチニブ |
| WO2025059602A1 (en) | 2023-09-14 | 2025-03-20 | Taris Biomedical Llc | Methods of treating bladder cancer using intravesical administration of erdafitinib |
| CN119219611B (zh) * | 2024-12-03 | 2025-04-18 | 南京诺源医疗器械有限公司 | 用于主动靶向成纤维细胞生长因子受体的近红外荧光探针及其制备方法与应用 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7135311B1 (en) | 1999-05-05 | 2006-11-14 | Institut Curie | Means for detecting and treating pathologies linked to FGFR3 |
| AU5214500A (en) | 1999-05-05 | 2000-11-21 | Centre National De La Recherche Scientifique (C.N.R.S.) | Means for detecting and treating pathologies linked to fgfr3 |
| CA2500255A1 (en) | 2002-10-01 | 2004-04-29 | Epigenomics Ag | Method and nucleic acids for the treatment of breast cell proliferative disorders |
| EP1611252B1 (en) * | 2003-03-26 | 2009-07-29 | Progenika Biopharma, S.A. | In vitro method to detect bladder transitional cell carcinoma |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| EP1659175A1 (en) * | 2004-11-18 | 2006-05-24 | Institut Curie | Alterations in seborrheic keratoses and their applications |
| EP2270000B1 (en) | 2005-05-23 | 2015-07-29 | Novartis AG | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts |
| WO2007061127A1 (ja) * | 2005-11-22 | 2007-05-31 | Eisai R & D Management Co., Ltd. | 多発性骨髄腫に対する抗腫瘍剤 |
| EP2546359A1 (en) * | 2005-12-08 | 2013-01-16 | Novartis AG | Effects of inhibitors of FGFR3 on gene transcription |
| EP1918376A1 (en) * | 2006-11-03 | 2008-05-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs |
| US20100075337A1 (en) | 2007-02-27 | 2010-03-25 | Diana Graus Porta | Method of identification of cells that show sensitivity to modulation of signalingh mediated by fibroblast growth factor receptor or a variant thereof |
| WO2008109369A2 (en) | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting tnf gene expression and uses thereof |
| US8163923B2 (en) | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
| JP5282088B2 (ja) | 2007-06-21 | 2013-09-04 | ジェン−プロウブ インコーポレイテッド | 処理実行に使用する機器および容器 |
| US8071338B2 (en) | 2007-08-08 | 2011-12-06 | Roche Molecular Systems, Inc. | Suppression of amplification using an oligonucleotide and a polymerase significantly lacking 5′-3′ nuclease activity |
| WO2013173480A1 (en) | 2012-05-15 | 2013-11-21 | Predictive Biosciences, Inc. | Detection of bladder cancer recurrence |
| WO2013173485A1 (en) | 2012-05-15 | 2013-11-21 | Predictive Biosciences, Inc. | Detection of bladder cancers |
| GB0718542D0 (en) | 2007-09-22 | 2007-10-31 | Univ Dundee | Targeted modulation of gene expression |
| AR073770A1 (es) | 2008-10-20 | 2010-12-01 | Imclone Llc | Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden |
| WO2010111625A1 (en) | 2009-03-27 | 2010-09-30 | Zymogenetics, Inc. | Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination |
| WO2011027219A1 (en) | 2009-09-04 | 2011-03-10 | Progenika Biopharma, S.A. | High throughput detection of small genomic deletions and insertions |
| EP2547698B1 (en) * | 2010-03-14 | 2015-07-29 | The Translational Genomics Research Institute | Methods of determining susceptibility of tumors to tyrosine kinase inhibitors |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| GB201020179D0 (en) * | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| CN102293770A (zh) * | 2011-05-25 | 2011-12-28 | 温州医学院 | 新型成纤维细胞生长因子受体酪氨酸激酶抑制剂 |
| CN102319224B (zh) * | 2011-07-27 | 2013-03-20 | 赛乐医药科技(上海)有限公司 | 复方甲氧那明的速释－缓释渗透泵制剂 |
| KR20140057343A (ko) | 2011-08-18 | 2014-05-12 | 네스텍 소시에테아노님 | 대립형질 변이 검출을 위한 조성물 및 방법 |
| EP2761300A4 (en) * | 2011-09-27 | 2015-12-02 | Univ Michigan | Recurrent genital fusion in breast cancer |
| AR088941A1 (es) | 2011-11-23 | 2014-07-16 | Bayer Ip Gmbh | Anticuerpos anti-fgfr2 y sus usos |
| WO2013088191A1 (en) * | 2011-12-12 | 2013-06-20 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3 |
| UA114501C2 (uk) * | 2012-02-28 | 2017-06-26 | Астеллас Фарма Інк. | Азотовмісна ароматична гетероциклічна сполука |
| BR112014021897B1 (pt) | 2012-03-08 | 2022-06-14 | Astellas Pharma Inc | Método, kit, conjunto de iniciadores e conjuntos de sondas para detectar um gene de fusão composto por um gene fgfr3 e um gene tacc3 |
| US9254288B2 (en) * | 2012-05-07 | 2016-02-09 | The Translational Genomics Research Institute | Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof |
| GB201209609D0 (en) * | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| EP2871236A4 (en) * | 2012-07-05 | 2016-03-09 | Nat Cancer Ct | FGFR2 fusion |
| ES2932954T5 (en) * | 2012-07-24 | 2025-10-28 | Univ Columbia | Fgfr-tacc fusion proteins and methods thereof |
| US20140030259A1 (en) * | 2012-07-27 | 2014-01-30 | Genentech, Inc. | Methods of treating fgfr3 related conditions |
| CA2886002C (en) * | 2012-09-27 | 2020-06-09 | Chugai Seiyaku Kabushiki Kaisha | Fgfr3 fusion gene and pharmaceutical drug targeting same |
| WO2014071419A2 (en) * | 2012-11-05 | 2014-05-08 | Foundation Medicine, Inc. | Novel fusion molecules and uses thereof |
| WO2014113729A2 (en) * | 2013-01-18 | 2014-07-24 | Foundation Mecicine, Inc. | Methods of treating cholangiocarcinoma |
| EP2981621B1 (en) | 2013-04-05 | 2019-05-22 | Life Technologies Corporation | Gene fusions |
| WO2014193229A2 (en) | 2013-05-27 | 2014-12-04 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Novel translocations in lung cancer |
| EP3019628A4 (en) | 2013-07-12 | 2017-05-10 | The Regents Of The University Of Michigan | Recurrent gene fusions in cancer |
| US20200208224A1 (en) | 2014-09-26 | 2020-07-02 | Janssen Pharmaceutica Nv | Use Of FGFR Mutant Gene Panels In Identifying Cancer Patients That Will Be Responsive To Treatment With An FGFR Inhibitor |
| CR20170104A (es) | 2014-09-26 | 2017-05-31 | Janssen Pharmaceutica Nv | Uso de paneles de genes mutantes de fgfr en la identificación de pacientes con cáncer que responderán al tratamiento con un inhibidor de fgfr |
| HRP20230697T1 (hr) | 2017-02-06 | 2023-10-13 | Janssen Pharmaceutica Nv | Liječenje karcinoma |
-
2015
- 2015-09-18 CR CR20170104A patent/CR20170104A/es unknown
- 2015-09-18 AU AU2015321626A patent/AU2015321626B2/en active Active
- 2015-09-18 HU HUE15782109A patent/HUE058219T2/hu unknown
- 2015-09-18 US US14/858,627 patent/US20160090633A1/en not_active Abandoned
- 2015-09-18 CN CN201580064601.1A patent/CN107002141B/zh active Active
- 2015-09-18 SM SM20220177T patent/SMT202200177T1/it unknown
- 2015-09-18 CA CA2962075A patent/CA2962075C/en active Active
- 2015-09-18 IL IL291633A patent/IL291633B2/en unknown
- 2015-09-18 PT PT157821091T patent/PT3198033T/pt unknown
- 2015-09-18 KR KR1020177010946A patent/KR102470456B1/ko active Active
- 2015-09-18 DK DK15782109.1T patent/DK3198033T3/da active
- 2015-09-18 RS RS20220400A patent/RS63178B1/sr unknown
- 2015-09-18 KR KR1020227040649A patent/KR102839867B1/ko active Active
- 2015-09-18 IL IL324511A patent/IL324511A/en unknown
- 2015-09-18 KR KR1020257024958A patent/KR20250119657A/ko active Pending
- 2015-09-18 MA MA40761A patent/MA40761B1/fr unknown
- 2015-09-18 MY MYPI2017700955A patent/MY194567A/en unknown
- 2015-09-18 CA CA3275619A patent/CA3275619A1/en active Pending
- 2015-09-18 HR HRP20220496TT patent/HRP20220496T1/hr unknown
- 2015-09-18 ES ES15782109T patent/ES2912567T3/es active Active
- 2015-09-18 SG SG11201702381QA patent/SG11201702381QA/en unknown
- 2015-09-18 SI SI201531836T patent/SI3198033T1/sl unknown
- 2015-09-18 UA UAA201704090A patent/UA122564C2/uk unknown
- 2015-09-18 WO PCT/US2015/050996 patent/WO2016048833A2/en not_active Ceased
- 2015-09-18 EA EA201790716A patent/EA037920B1/ru unknown
- 2015-09-18 EP EP15782109.1A patent/EP3198033B1/en active Active
- 2015-09-18 LT LTEPPCT/US2015/050996T patent/LT3198033T/lt unknown
- 2015-09-18 PL PL15782109.1T patent/PL3198033T3/pl unknown
- 2015-09-18 EP EP22156319.0A patent/EP4063516A1/en active Pending
- 2015-09-18 CN CN202111247854.6A patent/CN113957146B/zh active Active
- 2015-09-18 MX MX2017003954A patent/MX392774B/es unknown
- 2015-09-18 JP JP2017516458A patent/JP6766037B2/ja active Active
- 2015-09-22 JO JOP/2015/0238A patent/JO3681B1/ar active
- 2015-09-24 TW TW104131544A patent/TWI706136B/zh active
- 2015-09-24 AR ARP150103070A patent/AR102345A1/es unknown
- 2015-09-25 UY UY0001036325A patent/UY36325A/es active IP Right Grant
-
2017
- 2017-03-19 IL IL251264A patent/IL251264B/en unknown
- 2017-03-24 PH PH12017500556A patent/PH12017500556A1/en unknown
- 2017-03-24 NI NI201700035A patent/NI201700035A/es unknown
- 2017-03-24 SV SV2017005415A patent/SV2017005415A/es unknown
- 2017-03-24 MX MX2022006536A patent/MX2022006536A/es unknown
- 2017-03-24 GT GT201700059A patent/GT201700059A/es unknown
- 2017-04-12 CO CONC2017/0003528A patent/CO2017003528A2/es unknown
- 2017-04-25 ZA ZA2017/02899A patent/ZA201702899B/en unknown
- 2017-04-26 EC ECIEPI201725787A patent/ECSP17025787A/es unknown
-
2018
- 2018-09-19 US US16/136,201 patent/US12037644B2/en active Active
-
2020
- 2020-03-10 JP JP2020040708A patent/JP7051920B2/ja active Active
-
2021
- 2021-11-30 AU AU2021277633A patent/AU2021277633B2/en active Active
-
2022
- 2022-03-30 JP JP2022056709A patent/JP7558216B2/ja active Active
- 2022-04-29 CY CY20221100314T patent/CY1125190T1/el unknown
-
2024
- 2024-05-28 US US18/675,538 patent/US20240309463A1/en active Pending
- 2024-05-30 JP JP2024087917A patent/JP2024112991A/ja active Pending
-
2025
- 2025-02-28 AU AU2025201448A patent/AU2025201448A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017003954A (es) | Uso de paneles de genes mutantes de fgfr en la identificacion de pacientes con cancer que responderán al tratamiento con un inhibidor fgfr. | |
| PH12019502710A1 (en) | Fgfr2 inhibitors for the treatment of cholangiocarcinoma | |
| CO7151491A2 (es) | Método para la identificación del origen de un cancer de origen primario desconocido | |
| MX2024001734A (es) | Metodo de modificacion de diferenciacion e inmunidad de macrofagos. | |
| PH12019501942A1 (en) | Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor | |
| MX2017008421A (es) | Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga. | |
| HK1255533A1 (zh) | 用於检测大肠癌及进阶性腺瘤的蛋白质生物标志物面板 | |
| BR112017008453A2 (pt) | detecção automática de incompatibilidade de esquema | |
| NZ601606A (en) | Identification, assessment, and therapy of cancers with innate or acquired resistance to alk inhibitors | |
| EP4249608A3 (en) | Early lung cancer detection by dna methylation phenotyping of sputum-derived cells | |
| BR112018006393A2 (pt) | método para classificar um linfoma difuso de grande célula b (dlbcl), uma ou mais mídias de armazenamento legíveis por computador, sistema de computação adaptado e kit | |
| PH12017501064A1 (en) | Use of pan fgfr inhibitors and method of identifying patients with cancer eligible for treatment with a pan fgfr inhibitor | |
| PL408727A1 (pl) | Zestaw diagnostyczny i sposób jednoczesnego wykrywania mutacji w obrębie genu NF1 dla grupy pacjentów z podejrzeniem choroby Recklinghausena | |
| UA92246U (ru) | Спектрофотометрический способ количественного определения зопиклона | |
| AR104791A1 (es) | Métodos terapéuticos y diagnósticos para el cáncer | |
| PE20142434A1 (es) | Metodo para la identificacion del origen de un cancer de origen primario desconocido | |
| AR086571A1 (es) | Metodo para la identificacion del origen de un cancer de origen primario desconocido | |
| UA96044U (uk) | Спосіб прогнозування зрощення перелому |